Protective effects of dexpanthenol and y-27632 on stricture formation in a rat model of caustic esophageal injury.
BACKGROUND
This experimental study was conducted to investigate the effect of dexpanthenol (converted in the body to pantothenic acid) and Y-27632 (a selective Rho-kinase inhibitor) on stricture formation after caustic (alkaline) esophageal injury in rats.


METHODS
Sixty male Wistar albino rats were randomly allocated into six groups. In group 1 (sham) the distal esophagus was isolated and cannulated but no caustic injury was induced. In all remaining groups, a caustic esophageal burn was induced with 50% sodium hydroxide solution for 90 s and drug treatment was given by daily intraperitoneal injection, beginning 24 h after injury and continuing for 21 d. In group 2 (controls), animals were treated with 0.9% saline; in groups 3 and 4, with 50 and 500 mg/kg/d of dexpanthenol, respectively; and in groups 5 and 6, with 0.3 and 3 mg/kg/d of Y-27632, respectively. Rats were sacrificed 22 d after caustic injury and the distal esophagus was isolated for histopathology and biochemical investigation.


RESULTS
Stenosis index and collagen deposition scores were significantly lower in both the dexpanthenol and Y-27632 treated groups (P<0.05). Dexpanthenol and Y-27632 treatment markedly depressed esophageal tissue malondialdehyde and hydroxyproline levels.


CONCLUSIONS
In this experimental model of caustic esophageal stricture, dexpanthenol and Y-27632 significantly attenuated esophageal stricture formation. These findings indicate that inhibition of Rho-kinase or dexpanthenol administration may offer novel therapeutic approaches in the treatment of caustic esophageal injury.
Ceylan
Haluk
H
Department of Pediatric Surgery, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey. halukceylan@gmail.com
Yapici
Sefa
S
Tutar
Ediz
E
Ceylan
Nurdan Ozlu
NO
Tarakçıoğlu
Mehmet
M
Demiryurek
A Tuncay
AT
D000577:Amides / Q000494:pharmacology*; D000818:Animals; D002424:Caustics / Q000633:toxicity; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004940:Esophageal Stenosis / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D004947:Esophagus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012972:Sodium Hydroxide / Q000633:toxicity*; D014803:Vitamin B Complex / Q000494:pharmacology; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors
D000577:Amides; D002424:Caustics; D004791:Enzyme Inhibitors; D011725:Pyridines; D014803:Vitamin B Complex; C108830:Y 27632; D010205:Pantothenic Acid; C007288:dexpanthenol; D008315:Malondialdehyde; D012972:Sodium Hydroxide; D003094:Collagen; D054460:rho-Associated Kinases; D006909:Hydroxyproline